Search

Your search keyword '"van Leeuwen, Flora E."' showing total 376 results

Search Constraints

Start Over You searched for: Author "van Leeuwen, Flora E." Remove constraint Author: "van Leeuwen, Flora E." Database Unpaywall Remove constraint Database: Unpaywall
376 results on '"van Leeuwen, Flora E."'

Search Results

2. The mediating role of health behaviors in the association between depression, anxiety and cancer incidence: an individual participant data meta-analysis

4. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

5. Psychosocial factors, health behaviors and risk of cancer incidence: Testing interaction and effect modification in an individual participant data meta‐analysis

6. Prevalence of neoplasia at colonoscopy among testicular cancer survivors treated with platinum‐based chemotherapy

7. Reply to G. Wang et al

8. Risk of male breast cancer after Hodgkin lymphoma

9. Depression, anxiety, and the risk of cancer: An individual participant data meta‐analysis

10. Urinary incontinence more than 15 years after premenopausal risk‐reducing salpingo‐oophorectomy: a multicentre cross‐sectional study

12. The Areola study: design and rationale of a cohort study on long-term health outcomes in women with implant-based breast reconstructions

13. Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study

14. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

15. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

16. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

17. Supplementary Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

18. Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

19. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

20. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

21. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

22. Supplementary Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

23. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

24. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

25. Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

26. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

27. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

28. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

29. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

30. Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life

31. Surgical outcomes following breast reconstruction in patients with and without a history of chest radiotherapy for Hodgkin lymphoma: a multicentre, matched cohort study

32. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy

33. Supplementary Table S2 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

34. Data from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands

35. Supplementary Fig. S1 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

36. Supplementary Table S1 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

37. Supplementary Fig. S2 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

38. Supplementary Fig. S5 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

39. Supplementary Fig. S5 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

40. Supplementary Tables 1 through 5 from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands

41. Supplementary Tables 1-4 from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

42. Supplementary Fig. S2 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

43. Supplementary Fig. S4 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

44. Data from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands

45. Data from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

46. Supplementary Fig. S3 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

47. Supplementary Tables 1-4 from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

48. Supplementary Tables 1 through 5 from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands

49. Supplementary Material and Methods from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

50. Supplementary Fig. S4 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

Catalog

Books, media, physical & digital resources